Anakinra good for rheumatoid arthritis but also risky, says studyJanuary 21st, 2009 - 4:53 pm ICT by IANS
Washington, Jan 21 (IANS) Anakinra may be good for rheumatoid arthritis but a study warns that it also carries potential risks.The chronic inflammatory condition affects as many as one in 100 people worldwide, particularly the joints, making them stiff and painful.
Anakinra is one of a new breed of arthritis drugs licensed in the past decade called ‘biologics.’ The drug is the first to target the immune protein IL-1, thought to be partly responsible for inflammation in arthritis patients. It is given by daily injection.
In a Cochrane Systematic Review of five recent anakinra trials involving 2,876 patients, researchers found anakinra reduced pain and stiffness in patients, and helped to improve joint function, when compared to placebo.
However, while around a quarter of patients experienced improvement in their symptoms as a result of taking anakinra, the researchers said the improvements are notably less than those seen with other biologics.
Besides, there were more injection site reactions with the use of anakinra and the rate of serious infections with anakinra was approaching statistical significance when compared to placebo.
“We would recommend caution with the use of anakinra for rheumatoid arthritis, especially with only modest beneficial outcomes compared to other biologic medications studied for rheumatoid arthritis,” said lead researcher Marty Mertens of the University of Minnesota.
One study included in the review investigated the combination of anakinra with another biologic medication, etanercept. This found no benefits in arthritis outcomes, but did show a significant increase in the number of serious adverse events, said a Minnesota release.
“On the basis of these results, we recommend that doctors avoid combining biologic medications with anakinra when treating patients with rheumatoid arthritis,’ said Mertens.
- New rheumatoid arthritis drug offers modest benefit with some risk - Jan 21, 2009
- New drug limits brain damage in stroke - Jul 27, 2012
- Injectable gel could ease crippling joint pains - Apr 14, 2011
- New drug restores responsiveness to morphine - Jan 31, 2011
- Anti-depressants ease osteoarthritis pain - Mar 23, 2012
- Celebrex shows potential in preventing some skin cancers - Dec 01, 2010
- Frequent tipple halves rheumatoid arthritis risk - Jul 11, 2012
- Aerobic exercise beneficial for rheumatoid arthritis patients - Jun 25, 2010
- 'Homeopathy tricks you into feeling better' - Nov 15, 2010
- Obesity epidemic behind rheumatoid arthritis - Apr 26, 2012
- Arthritis invites higher risk of heart attacks - Mar 09, 2012
- Cholesterol drugs lessen arthritis risk, finds study - Sep 08, 2010
- Rheumatoid arthritis medication linked to increased risk for shingles - Feb 18, 2009
- Cuba develops anti-arthritis drug - Feb 17, 2011
- Regular statin use 'cuts rheumatoid arthritis risk' - Sep 08, 2010
Tags: anakinra, arthritis, arthritis drugs, arthritis patients, chronic inflammatory condition, cochrane, immune protein, inflammation, jan 21, joints, medications, mertens, new breed, patients with rheumatoid arthritis, placebo, rheumatoid arthritis, serious adverse events, statistical significance, stiffness, university of minnesota